FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Mastercard Asks Brazil's Payment Processors to Help Pay for Banco Master Failure

By

Mastercard (MA) is looking to minimize its losses from Banco Master's failure by asking some of Brazil's largest payment processors to help foot the bill, Bloomberg reported Friday, citing people familiar with the matter and documents it viewed.

Mastercard was the network for the cards issued by Banco Master's fintech, Will Financeira, which collapsed and left the payment company responsible for reimbursing merchant acquirers that processed about 5 billion reais ($997 million) of cardholder payments, the report said.

Mastercard has already paid back payment processors for about half of that amount, but it's now proposing that it will use any money collected from card customers to reimburse itself before passing further funds to those merchant acquirers, the report said, citing the people and the documents.

Mastercard didn't immediately reply to requests for comment from.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $500.31, Change: $+0.69, Percent Change: +0.14%

Related Articles

Wire

AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer

AstraZeneca (AZN) and Daiichi Sankyo said Friday that the US Food and Drug Administration has approved Datroway for first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.The approval followed the FDA's priority review based on phase 3 data showing Datroway, or datopotamab deruxtecan, improved median overall survival to 23.7 months compared with 18.7 months for patients treated with chemotherapy, the companies said.Datroway also reduced the risk of disease progression or death by 43%, with median progression-free survival of 10.8 months versus 5.6 months for chemotherapy, according to the companies.The safety profile of Datroway was evaluated in 319 patients, with serious adverse reactions including pneumonia, vomiting, COVID-19 and anemia reported in more than 1% of patients, while one fatality was linked to interstitial lung disease or pneumonitis, Daiichi Sankyo said.Datroway is a TROP2-directed antibody drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialized with AstraZeneca.Shares of AstraZeneca were down 1.4% in Friday trading.Price: $187.16, Change: $-2.59, Percent Change: -1.36%

$AZN
Wire

Raymond James Adjusts Price Target on Deere to $700 From $765, Maintains Outperform Rating

Deere (DE) has an average rating of overweight and mean price target of $666.01, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $524.61, Change: $-6.75, Percent Change: -1.27%

$DE
Wire

Update: BJ's Wholesale Shares Fall as Fiscal Q1 Adjusted Earnings Decline

(Updates with stock move in headline and first paragraph.)BJ's Wholesale Club shares fell more than 6% in Friday morning trading after fiscal Q1 adjusted earnings declined year over year, even as revenue rose and results beat analysts' estimates.The company reported fiscal Q1 adjusted earnings earlier Friday of $1.10 per diluted share, down from $1.14 a year earlier. Analysts polled by FactSet expected $1.03.Revenue for the quarter ended May 2 was $5.66 billion, up from $5.15 billion a year earlier. Analysts surveyed by FactSet expected $5.44 billion.For fiscal 2026, the company continues to expect adjusted EPS of $4.40 to $4.60. Analysts polled by FactSet expect $4.51.Price: $87.44, Change: $-7.00, Percent Change: -7.41%

$BJ